340B Drug Pricing Program
November 5, 2021
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
ORDERED that the plaintiffs' Motions for Summary Judgment, Dkt. 19 (Novartis), Dkt. 14 (United Therapeutics) are GRANTED IN PART and DENIED IN PART.
This case concerns conditions that plaintiffs Novartis Pharmaceuticals Corporation and
United Therapeutics Corporation have imposed on discounted drug purchases by certain safetynet
health care providers.
The Centers for Medicare & Medicaid Services (CMS) yesterday released its calendar year (CY) 2022 outpatient prospective payment system (OPPS)/ambulatory surgical center (ASC) final rule that updates payment rates and makes several policy changes, generally effective on Jan 1, 2022.
The Centers for Medicare & Medicaid Services (CMS) yesterday released its calendar year (CY) 2022 outpatient prospective payment system (OPPS)/ambulatory surgical center (ASC) final rule that updates payment rates and makes several policy changes, generally effective on Jan 1, 2022.
A federal district court judge in Indiana Friday agreed with the government’s contention that the 340B statute would permit the Department of Health and Human Services to require that the drug company Eli Lilly offer 340B discounts for drugs distributed by hospitals through community pharmacies,…
Court Order in the Lilly Challenge October 29, 2021
Court Decision on the Lilly Challenge October 29, 2021
Government responds to Hospital 340B Payment Reduction Challenge (Oct. 20, 2021).
The AHA and five other groups late Friday expressed continued support for the 340B drug pricing program and strongly encouraged Congress to protect the program as it considers broader changes to the nation’s health care system as part of a legislative package under reconciliation.